Compare Global X CleanTech (CTEC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs TG Therapeutics Inc — how do they compare? Global X CleanTech trades at $60.14, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| CTEC | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $59.06 |
52-Week Low | $41.08 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $60.14, up 3.68% today, with a bullish technical signal from moving averages but bearish oscillators. Key resistance is at $60, with support at $58. The company has announced a dividend of $0.07 per share payable in July 2026. Financial ratios such as P/E and P/S are not available in the provided data.
The outlook is mixed; technical strength suggests potential near-term gains, but overbought RSI signals caution. The dividend announcement may attract income investors. Risks include reliance on technical momentum without clear fundamental data and market volatility. Investors need updated financials for a complete assessment.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
